266 related articles for article (PubMed ID: 20625718)
1. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms.
Nagant C; Tré-Hardy M; El-Ouaaliti M; Savage P; Devleeschouwer M; Dehaye JP
Appl Microbiol Biotechnol; 2010 Sep; 88(1):251-63. PubMed ID: 20625718
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
[TBL] [Abstract][Full Text] [Related]
3. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
Thellin O; Zorzi W; Jolois O; Elmoualij B; Duysens G; Cahay B; Streel B; Charif M; Bastin R; Heinen E; Quatresooz P
Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
6. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
[TBL] [Abstract][Full Text] [Related]
7. Effects of iron depletion on antimicrobial activities against planktonic and biofilm Pseudomonas aeruginosa.
Cai Y; Yu XH; Wang R; An MM; Liang BB
J Pharm Pharmacol; 2009 Sep; 61(9):1257-62. PubMed ID: 19703377
[TBL] [Abstract][Full Text] [Related]
8. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.
Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A
Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299
[TBL] [Abstract][Full Text] [Related]
9. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa.
Alipour M; Dorval C; Suntres ZE; Omri A
J Pharm Pharmacol; 2011 Aug; 63(8):999-1007. PubMed ID: 21718282
[TBL] [Abstract][Full Text] [Related]
10. In vitro effectiveness of the antibiotic lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae.
Lee MY; Ko KS; Song JH; Peck KR
J Antimicrob Chemother; 2007 Oct; 60(4):782-7. PubMed ID: 17681978
[TBL] [Abstract][Full Text] [Related]
11. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Guzel C; Savage PB; Gerceker AA
Chemotherapy; 2011; 57(6):505-10. PubMed ID: 22286090
[TBL] [Abstract][Full Text] [Related]
13. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A
Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin.
Eckert R; Brady KM; Greenberg EP; Qi F; Yarbrough DK; He J; McHardy I; Anderson MH; Shi W
Antimicrob Agents Chemother; 2006 Nov; 50(11):3833-8. PubMed ID: 16940063
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.
Peeters E; Nelis HJ; Coenye T
J Antimicrob Chemother; 2009 Oct; 64(4):801-9. PubMed ID: 19633000
[TBL] [Abstract][Full Text] [Related]
16. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
[TBL] [Abstract][Full Text] [Related]
17. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Treerat P; Widmer F; Middleton PG; Iredell J; George AM
FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
[TBL] [Abstract][Full Text] [Related]
18. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
Field TR; White A; Elborn JS; Tunney MM
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
[TBL] [Abstract][Full Text] [Related]
19. Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada.
Beaudoin T; Aaron SD; Giesbrecht-Lewis T; Vandemheen K; Mah TF
Can J Microbiol; 2010 Jul; 56(7):548-57. PubMed ID: 20651854
[TBL] [Abstract][Full Text] [Related]
20. Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa.
Al-Bakri AG; Gilbert P; Allison DG
J Basic Microbiol; 2005; 45(5):392-6. PubMed ID: 16187262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
